Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62990 | 0.88 | HSD17B10 (0.52) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| SCHEMBL337070 | 0.88 | HSD17B10 (0.52) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| SCHEMBL472190 | 0.86 | CHRM5 (0.50) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| SCHEMBL306395 | 0.86 | CHRM5 (0.50) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| Hydrochloric Acid SCHEMBL31505485 | 0.86 | CHRM5 (0.50) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| Hydrochloric Acid SCHEMBL4441607 | 0.86 | CHRM5 (0.50) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| SCHEMBL472213 | 0.86 | CHRM5 (0.50) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| Hydrochloric Acid SCHEMBL1373260 | 0.86 | CHRM5 (0.50) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| Water SCHEMBL4953290 | 0.86 | CHRM5 (0.50) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C | |
| SCHEMBL29299554 | 0.86 | CHRM5 (0.50) | SIGMAR1CHRM5CHRM3HSD17B10KDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | SIGMAR1 26/4885CHRM5 172/4885CHRM3 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.